Skip to main content
    Eli Lilly logo

    Eli Lilly

    Health care

    TickerLLYISINUS5324571083

    Eli Lilly stock analysis: how the business works, what moves it and what to check

    How Eli Lilly makes money, what moves the stock, which figures to check and the risks to keep in view.

    Peakwise Research · · Updated · 5 min read

    Contents

    Eli Lilly became one of the most valuable drug makers in the world on the back of its diabetes and obesity medicines. The stock carries high expectations, so what matters is whether supply, pricing and the pipeline keep up with them.

    CompanyEli Lilly and Company
    TickerLLY
    ListingNYSE
    SectorHealth Care
    ISINUS5324571083
    HeadquartersIndianapolis, Indiana, USA

    Eli Lilly at a glance

    • GLP-1 medicines for diabetes and obesity drive growth.
    • Large investments in new factories to meet demand.
    • The valuation already assumes strong growth for years.

    A short history

    Colonel Eli Lilly founded the company in Indianapolis in 1876. It was the first to mass-produce insulin in the 1920s and later developed medicines such as Prozac. In 2022 and 2023 its GLP-1 medicines Mounjaro (diabetes) and Zepbound (obesity) were approved, and demand turned Lilly into the most valuable pharmaceutical company in the world.

    How Eli Lilly makes money

    Lilly sells prescription medicines across diabetes, obesity, oncology, immunology and neuroscience. The incretin drugs based on tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, have become the largest revenue drivers.

    Competitive position

    Lilly and Novo Nordisk lead the market for GLP-1 medicines, protected by patents and by the difficulty of manufacturing these drugs at scale. Lilly's tirzepatide has shown strong weight loss in trials, and it is developing oral options. New competitors are entering, including Amgen, Pfizer, Roche and many biotech firms, and compounded versions have been a factor in the US.

    What moves Eli Lilly stock

    • Obesity and diabetes demand. Sales of the incretin drugs drive most of the growth.
    • Manufacturing capacity. Lilly has invested heavily in new plants to meet demand.
    • Pipeline. Oral weight-loss pills and other late-stage trials can extend growth.
    • Pricing and coverage. Insurance coverage and US drug pricing policy affect sales.

    Eli Lilly key figures, up to date

    LLY

    The AI stock analysis computes these figures from current market data, with a short comment on each number and the method behind the fair value range.

    Free for 7 days. Not investment advice.

    The numbers worth checking

    Not every ratio matters equally for every company. For Eli Lilly, these are the figures that tell you the most. If a term is new, the guides on the P/E ratio and fair value explain the basics.

    • Revenue by product. Shows how concentrated growth is.
    • Gross margin. Reflects pricing and manufacturing scale.
    • R&D spending. Lilly spends a large share of revenue on research.
    • Forward P/E. Very high expectations are priced in, so compare with growth.

    The best source for these figures is the latest annual or quarterly report on the Eli Lilly investor relations site. Our guide on how to read an earnings report shows where to find them.

    How to think about valuation

    Lilly is valued on expected future earnings rather than today's, so the P/E looks high. Investors model how many patients will use obesity medicines, at what price and for how long. Sensitivity to price assumptions is high.

    Opportunities

    • Obesity market. Hundreds of millions of people could qualify for treatment.
    • New indications. Trials in heart, sleep apnoea and other conditions widen use.
    • Oral options. Pills could reach patients who avoid injections.

    Risks to keep in view

    • Competition. Novo Nordisk and new entrants compete in obesity drugs.
    • Drug pricing pressure. US policy and negotiations can lower prices.
    • Concentration. A large share of growth depends on one drug class.

    A useful exercise is to write the bull case and the bear case for Eli Lilly in three sentences each. If you cannot fill the bear case, you have not looked hard enough. How to write an investment thesis walks through it.

    What to watch in the next report

    • Mounjaro and Zepbound sales
    • Manufacturing capacity updates
    • Pricing and reimbursement news, especially in the US

    How to research Eli Lilly stock with Peakwise

    Open the AI stock analysis and look up LLY. You get financials, news, analyst consensus, a fair value range (low, mid and high, with the method stated) and a list of risks and opportunities for Eli Lilly, plus a chat next to the report for follow-up questions.

    Eli Lilly is also one of the 50 large S&P 500 companies with a daily AI stock score for Eli Lilly. It ranks the stock from 0 to 100 against the rest of that list on momentum, trend, volatility, drawdown, quality and valuation, updated once per trading day from end of day prices. How the score is built.

    For anything the report leaves open, ask the investment chatbot. It runs a web search for each question and links the sources it used, so you can open them and check. A good first question:

    What were Mounjaro and Zepbound sales last quarter and how did Lilly describe supply?

    To look at the chart itself, the AI chart analysis describes trend, support and resistance levels and patterns over one month, one year and the full history.

    This article describes the business and the questions worth asking. It contains no price targets and no forecasts, and it is not investment advice. Check current figures before you make a decision.

    Frequently asked questions

    The fastest growing are tirzepatide medicines sold as Mounjaro and Zepbound. Lilly also sells cancer drugs such as Verzenio and immunology and neuroscience medicines.

    That depends on your goals, your time horizon and the price you pay, so no article can answer it for you. For Eli Lilly, the points that carry the most weight are obesity and diabetes demand, manufacturing capacity and, on the risk side, competition. Check them with current figures and decide for yourself. This is not investment advice.

    Competition. Novo Nordisk and new entrants compete in obesity drugs. Drug pricing pressure. US policy and negotiations can lower prices. Concentration. A large share of growth depends on one drug class.

    On the Eli Lilly page in the Peakwise stock section. The score ranks Eli Lilly from 0 to 100 against 50 large S&P 500 companies and is updated once per trading day. It describes past data and is not a recommendation.

    Eli Lilly and Company trades under the ticker LLY. The ISIN is US5324571083. Listing: NYSE.

    Check Eli Lilly yourselfin one report

    The AI stock analysis puts financials, news, analyst consensus, a fair value range with its method, and risks and opportunities in one report.

    Free for 7 days. Not investment advice.